19 Jun 2008 17:26
RNS Number : 1421X
ReGen Therapeutics PLC
19 June 2008
Β
Β
19th June 2008
Β
REGEN THERAPEUTICS PLC
(βReGenβ or the βCompanyβ; Ticker: (RGT))
Β
Β
TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES
Β
Β
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):
Β
ReGen Therapeutics Plc
Β
2. Reason for the notification:
Β
An acquisition or disposal of voting rights
Β
3. Full name of person(s) subject to the notification obligation (iii):
Β
Andrew Clement Wilson
Β
4. Full name of shareholder(s) (if difference from 3):
Β
As above
Β
5. Date of the transaction and date on which the threshold is crossed or reached (v):
Β
18 June 2008
Β
6. Date on which issued notified:
Β
19 June 2008
Β
7. Threshold(s) that is/are crossed or reached:
Β
13%
8. Notified details Β
A: Voting rights attached to shares
Β
Class/type of share if possible using the ISIN Code GB00B28XMY25
Β
Situation Previous to the triggering transaction (vi) β
Number of Shares 1,477,000
Number of Voting Rights (viii) 1,477,000
Β
Resulting situation after the triggering transaction (viii) β
Number of Shares 1,495,000
Number of Voting Rights β Direct (x) 1,495,000
Number of Voting Rights β Indirect (xi) N/A
% of voting rights β Direct 13.02%
% of voting rights β Indirect N/A
B: Financial Instruments Resulting situation after the triggering transaction (xii)
Β
Type of financial instrument N/A
Β
Expiration date (xiii) N/A
Β
Exercise/Conversion Period/Date (xiv) N/A
Β
Number of voting rights that may be acquired if the
instrument is exercised/converted N/A
Β
% of voting rights N/A
Total (A+B)
Β
Number of voting rights 1,495,000
Β
% of voting rights 13.02
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):
Β
Shares are held in own name
Β
Proxy Voting:
Β
10. Name of the proxy holder: N/A
Β
11. Number of voting rights proxy holder will cease to hold: N/A
Β
12. Date on which proxy holder will cease to hold voting rights: N/A
Β
13. Additional information: N/A
Β
14. Contact name: N/A
Β
15. Contact telephone number: N/A
Β
Β
For further information:
Β
Percy Lomax
ReGen Therapeutics Plc
Tel: +44 (0) 207 153 4920
Β
Roland Cornish / Felicity Geidt
Beaumont Cornish Limited
Tel: +44(0) 207 628 3396
Β
Β
This information is provided by RNS
The company news service from the London Stock Exchange
Β
ENDΒ
Β
MSCFKCKDABKDCAD
Follow the stocks